Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 257

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study

Open access
Silberstein, Stephen D., Calhoun, Anne H., Lipton, Richard B., Grosberg, Brian M., Cady, Roger K., Dorlas, Stefanie, Simmons, Kristy A., Mullin, Chris, Liebler, Eric J., Goadsby, Peter J., Saper, Joel R., EVENT Study Group, Calhoun, Anne H., Cady, Roger K., Dexter, John, Silberstein, Stephen D., Young, William, Marmura, Michael, Nahas-Geiger, Stephanie, Da Silva, Arnaldo, Saper, Joel, Weintraub, James, Prestegaard, Alicia, Sinka, Erik, Grosberg, Brian, Vollbracht, Sarah, Issa, Shirin, Lipton, Richard, Mullin, Kathleen, Pavlovic, Jelena, Robbins, Matthew, Goadsby, Peter, Gelfand, Amy, Eller, Michael · 2016 · Neurology

Abstract

OBJECTIVE: To evaluate the feasibility, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS) for the prevention of chronic migraine (CM) attacks. METHODS: In this first prospective, multicenter, double-blind, sham-controlled pilot study of nVNS in CM prophylaxis, adults with CM (≥15 headache d/mo) entered the baseline phase (1 month) and were subsequently randomized to nVNS or sham treatment (2 months) before receiving open-label nVNS treatment (6 months). The primary endpoints were safety and tolerability. Efficacy endpoints in the intent-to-treat population included change in the number of headache days per 28 days and acute medication use. RESULTS: Fifty-nine participants (mean age, 39.2 years; mean headache frequency, 21.5 d/mo) were enrolled. During the randomized phase, tolerability was similar for nVNS (n = 30) and sham treatment (n = 29). Most adverse events were mild/moderate and transient. Mean changes in the number of headache days were -1.4 (nVNS) and -0.2 (sham) (Δ = 1.2; p = 0.56). Twenty-seven participants completed the open-label phase. For the 15 completers initially assigned to nVNS, the mean change from baseline in headache days after 8 months of treatment was -7.9 (95% confidence interval -11.9 to -3.8; p < 0.01). CONCLUSIONS: Therapy with nVNS was well-tolerated with no safety issues. Persistent prophylactic use may reduce the number of headache days in CM; larger sham-controlled studies are needed. CLINICALTRIALSGOV IDENTIFIER: NCT01667250. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, nVNS is safe, is well-tolerated, and did not significantly change the number of headache days. This pilot study lacked the precision to exclude important safety issues or benefits of nVNS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000002918

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 257

Metadata

Authors
Silberstein, S. D., Calhoun, A. H., Lipton, R. B., Grosberg, B. M., Cady, R. K., Dorlas, S., Simmons, K. A., Mullin, C., Liebler, E. J., Goadsby, P. J., Saper, J. R., EVENT Study Group, Calhoun, A. H., Cady, R. K., Dexter, J., Silberstein, S. D., Young, W., Marmura, M., Nahas-Geiger, S., Da Silva, A., Saper, J., Weintraub, J., Prestegaard, A., Sinka, E., Grosberg, B., Vollbracht, S., Issa, S., Lipton, R., Mullin, K., Pavlovic, J., Robbins, M., Goadsby, P., Gelfand, A., & Eller, M.
Venue
Neurology
Published
2016-08-02
Volume
87
Issue
5
Pages
529-538
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2466591301
Cited by
257
References
28
FWCI
23.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. https://app.cochat.ai/papers/10.1212/wnl.0000000000002918
The paper
Silberstein, S. D., Calhoun, A. H., Lipton, R. B., Grosberg, B. M., Cady, R. K., Dorlas, S., Simmons, K. A., Mullin, C., Liebler, E. J., Goadsby, P. J., Saper, J. R., EVENT Study Group, Calhoun, A. H., Cady, R. K., Dexter, J., Silberstein, S. D., Young, W., Marmura, M., Nahas-Geiger, S., . . . Eller, M. (2016). Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. https://doi.org/10.1212/wnl.0000000000002918

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.